Keywords: Novartis, Alisporivir, Hepatitis C, Debiopharm

Novartis’ alisporivir may become first interferon-free oral for hepatitis C G2/G3

Article | 14 November 2011

Print This

The clear conclusion from a clinical trial of alisporivir (DEB025, from Swiss drug major Novartis [NOVN: VX]), an oral host-targeting ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in